Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
EAGLE PHARMACEUTICALS, INC. (EGRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
08/17/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP EPS 1 Guidance -- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million 1 -- -- FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.70 1 -- -- Reflects strength of Eagle’ s business and product pipeline; Company poised for sustained long-term growth – WOODCLIFF LAKE, N.J. — August 17, 2023 — Eagle Pharmaceuticals, Inc. today reiterated its previously issued guidance for the 2023 fiscal year. Full-year 2023 Adjusted non-GAAP EBITDA is expected to range from $78.0 to $84.0 million and Adjusted non-GAAP earnings per share is expected to range from $4.40 to $4.70. “Based on the strength of our business and product pipeline, we are reiterating our recently increased guidance ..."
08/08/2023 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports Second Quarter 2023 Results · Total revenue for Q2 2023 was $64.6 million · Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income 1 was $1.18 per basic and diluted share · Q2 2023 net income was $5.2 million · Q2 2023 adjusted non-GAAP EBITDA 1 was $20.7 million · Gross margin was 74% for the first half of 2023, up from 73% for the first half of 2022 · Adjusted non-GAAP gross margin 1 was 83% for the first half of 2023, up from 74% for the first half of 2022 · Gross profit in its oncology business was $41.9 million in the second quarter of 2023 compared with $38.7 million in the prior year period, representing gross margin of 80% and 72%, respectively · Adjusted non-GAA..."
07/31/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
07/18/2023 8-K Regulation FD Disclosure  Interactive Data
06/30/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/09/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
06/06/2023 8-K Investor presentation
Docs: "2016 2017 2018 2019 2020 2021 2022 2023E"
05/09/2023 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports First Quarter 2023 Results · Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022 · Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income 1 was $1.27 per basic and $1.26 per diluted share · Q1 2023 adjusted non-GAAP EBITDA of $22.3 million · Q1 2023 net sales of PEMFEXY totaled $22.9 million; Eagle estimates that it has an approximate 15% share in commercial pemetrexed market for the second quarter of 2023 to date 2 · BENDEKA ®3 and BELRAPZO ®4 - both ready-to-dilute products — combined maintained approximately 89% share of the bendamustine U.S. market for the first quarter of 2023 compared to approximately 90% historically 5 · Company reaffirms full yea..."
05/01/2023 8-K Quarterly results
03/13/2023 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results · Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share 1 · Total revenue for Q4 2022 was $60.7 million, compared to $42.3 million in Q4 2021 · FY 2022 net income was $2.76 per basic and $2.73 per diluted share and adjusted non-GAAP net income was $7.87 per basic and $7.79 per diluted share 1 · FY 2022 revenue was $316.6 million compared to $171.5 million in FY 2021 · FY 2022 net sales of PEMFEXY ® totaled $67.5 million, and were $12.1 million in Q4 2022, representing a 6% U.S. market share in community oncology at the end of Q4 2022; already captured a 10% share through February 2023; antici..."
01/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Eagle Pharmaceuticals Provides Business Update and Guidance for 2023 Woodcliff Lake, N.J. – January 10, 2023 -- Eagle Pharmaceuticals, Inc. today provided a business update and guidance for 2023. Highlights: · During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 per diluted share and adjusted EBITDA of $125.6 million and non-GAAP earnings per diluted share of $7.54, a significant increase from 2021. 1 · Eagle exited 2022 with an approximate 6% 2 share of the commercial segment of the pemetrexed market for its PEMFEXY ® product, equating to approximately $8 million per quarter in revenue 3 , and anticipates doubling its share by end of Q1 2023. The Company bought down future royalties on PEMFEXY profits in exchange for one-time pa..."
01/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "2016 2017 2018 2019 2020 2021 LTM 9.30.22 2023E"
12/19/2022 8-K Quarterly results
12/14/2022 8-K Quarterly results
12/12/2022 8-K Quarterly results
12/09/2022 8-K Quarterly results
12/06/2022 8-K Quarterly results
11/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia"
11/07/2022 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports Third Quarter 2022 Results · Q3 2022 net loss was $ per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share 1 · Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021 · Nine-month 2022 net income was $2.41 per basic and $2.38 per diluted share · Nine-month 2022 adjusted non-GAAP earnings per diluted share 1 more than doubled to $6.69 from full year 2021 adjusted non-GAAP earnings per diluted share, outperforming any full year in the Company’ s history · Nine-month 2022 revenue of $255.9 million exceeds full year 2021 revenue of $171.5 million · Nine-month 2022 net sales of vasopressin and PEMFEXY combined totaled $114.9 million · BEN..."
11/02/2022 8-K Quarterly results
10/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial Pneumonia -- Company plans to commence an adequately powered Phase 2 study with approximately 276 patients with severe community-acquired pneumonia at 120 sites worldwide with patient enrollment expected as early as the beginning of 2023 -- -- Interim results expected approximately one year after patient enrollment begins -- -- CAL02 is being developed as an add-on to the clinically indicated antibiotic treatment and potentially offers unique therapeutic benefits to critically ill patients, including immediate decrease in inflammatory biomarkers, ..."
10/03/2022 8-K Quarterly results
09/27/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advance an Intramuscular Formulation of ENA-001"
08/18/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
08/01/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/18/2022 8-K Quarterly results
07/18/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy